Spero Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Spero Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2023-12-31 was $1.00K, a 99.97% decline year-over-year.
- Spero Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2023-09-30 was $220.00K, a 96.41% decline year-over-year.
- Spero Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2022-12-31 was $3.90M, a 57.76% increase year-over-year.
- Spero Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2022-09-30 was $6.13M, a 454.57% increase year-over-year.
- Spero Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2023 was $221.00K, a 98.45% decline from fiscal 2022.
- Spero Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2022 was $14.23M, a 81.76% increase from fiscal 2021.
- Spero Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2021 was $7.83M, a 89.95% decline from fiscal 2020.
- Spero Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2020 was $77.93M, a 408.81% increase from fiscal 2019.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2023-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $221.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | $220.00K 10-Q · filed 2024-11-14 | |
| 2022-12-31 | $3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $14.23M 10-K · filed 2024-03-13 |
| 2022-09-30 | $6.13M 10-Q · filed 2023-11-13 | $12.80M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $577.00K 10-Q · filed 2023-08-10 | $7.78M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $3.63M 10-Q · filed 2023-05-11 | $7.21M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $2.47M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $7.83M 10-K · filed 2023-03-30 |
| 2021-09-30 | $1.10M 10-Q · filed 2022-11-14 | $20.53M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $65.83M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $4.12M 10-Q · filed 2022-05-16 | $73.10M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $15.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $77.93M 10-K · filed 2022-03-31 |
| 2020-09-30 | $46.40M 10-Q · filed 2021-11-10 | $68.13M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $7.27M 10-Q · filed 2021-08-05 | $21.77M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $8.96M 10-Q · filed 2021-05-06 | $22.75M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $5.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $15.32M 10-K · filed 2021-03-11 |
| 2019-09-30 | $38.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $8.25M 10-Q · filed 2020-08-06 | |
| 2019-03-31 | $1.52M 10-Q · filed 2020-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |